Corcept End Period Cash Flow vs Capital Expenditures Analysis

CORT Stock

USD 52.47 1.16 2.16%

Corcept Therapeutics financial indicator trend analysis is way more than just evaluating Corcept Therapeutics prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Corcept Therapeutics is a good investment. Please check the relationship between Corcept Therapeutics End Period Cash Flow and its Capital Expenditures accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

End Period Cash Flow vs Capital Expenditures

End Period Cash Flow vs Capital Expenditures Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Corcept Therapeutics End Period Cash Flow account and Capital Expenditures. At this time, the significance of the direction appears to have weak contrarian relationship.

The correlation between Corcept Therapeutics' End Period Cash Flow and Capital Expenditures is -0.05. Overlapping area represents the amount of variation of End Period Cash Flow that can explain the historical movement of Capital Expenditures in the same time period over historical financial statements of Corcept Therapeutics Incorporated, assuming nothing else is changed. The correlation between historical values of Corcept Therapeutics' End Period Cash Flow and Capital Expenditures is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which End Period Cash Flow of Corcept Therapeutics Incorporated are associated (or correlated) with its Capital Expenditures. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Capital Expenditures has no effect on the direction of End Period Cash Flow i.e., Corcept Therapeutics' End Period Cash Flow and Capital Expenditures go up and down completely randomly.

Correlation Coefficient

-0.05

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

End Period Cash Flow

Capital Expenditures

Capital Expenditures are funds used by Corcept Therapeutics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Corcept Therapeutics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most indicators from Corcept Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Corcept Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Corcept Therapeutics Incorporated. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.

Selling General Administrative is likely to gain to about 193.1 M in 2024. Tax Provision is likely to gain to about 19.3 M in 2024

	2021	2022	2023	2024 (projected)
Other Operating Expenses	241.5M	289.2M	375.1M	393.8M
Research Development	113.9M	131.0M	184.4M	193.6M

Other Operating Expenses Research Development

Corcept Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Accounts Payable	Cash	Other Current Assets	Total Liab	Common Stock	Property Plant Equipment	Total Stockholder Equity	Other Assets	Common Stock Shares Outstanding	Other Stockholder Equity	Short Term Investments	Short Long Term Debt Total	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments	Common Stock Total Equity	Non Current Liabilities Total	Property Plant And Equipment Gross	Total Current Assets	Current Deferred Revenue
Total Assets		0.76	0.75	0.93	0.74	0.82	0.82	0.5	0.98	1.0	0.85	0.4	-0.16	0.93	-0.73	0.51	-0.76	0.9	0.86	0.96	0.97	0.52	0.03	0.46	0.99	0.86
Other Current Liab	0.76		0.89	0.82	0.3	0.9	0.84	0.34	0.77	0.73	0.79	0.21	-0.47	0.58	-0.59	0.08	-0.33	0.83	0.88	0.76	0.64	0.38	-0.25	-0.05	0.69	0.8
Total Current Liabilities	0.75	0.89		0.87	0.19	0.93	0.91	0.32	0.81	0.7	0.75	0.17	-0.36	0.6	-0.49	0.11	-0.22	0.75	0.91	0.69	0.6	0.36	-0.37	0.0	0.66	0.81
Accounts Payable	0.93	0.82	0.87		0.48	0.87	0.89	0.43	0.94	0.91	0.89	0.33	-0.23	0.79	-0.64	0.3	-0.51	0.87	0.97	0.83	0.83	0.47	-0.08	0.24	0.87	0.89
Cash	0.74	0.3	0.19	0.48		0.37	0.31	0.55	0.64	0.78	0.52	0.53	0.23	0.87	-0.56	0.74	-1.0	0.54	0.31	0.77	0.86	0.52	0.23	0.73	0.82	0.44
Other Current Assets	0.82	0.9	0.93	0.87	0.37		0.91	0.3	0.87	0.78	0.73	0.12	-0.49	0.7	-0.53	0.09	-0.4	0.88	0.86	0.81	0.72	0.33	-0.15	0.0	0.76	0.78
Total Liab	0.82	0.84	0.91	0.89	0.31	0.91		0.43	0.88	0.76	0.68	0.27	-0.32	0.64	-0.41	0.13	-0.34	0.8	0.88	0.83	0.72	0.48	0.0	0.05	0.76	0.77
Common Stock	0.5	0.34	0.32	0.43	0.55	0.3	0.43		0.44	0.48	0.33	0.97	0.54	0.47	-0.1	0.36	-0.53	0.18	0.33	0.56	0.51	0.99	0.16	0.33	0.51	0.38
Property Plant Equipment	0.98	0.77	0.81	0.94	0.64	0.87	0.88	0.44		0.97	0.83	0.31	-0.24	0.9	-0.68	0.44	-0.67	0.92	0.88	0.94	0.94	0.47	0.01	0.39	0.96	0.86
Total Stockholder Equity	1.0	0.73	0.7	0.91	0.78	0.78	0.76	0.48	0.97		0.86	0.39	-0.15	0.95	-0.76	0.56	-0.8	0.9	0.82	0.94	0.98	0.5	0.02	0.51	0.99	0.85
Other Assets	0.85	0.79	0.75	0.89	0.52	0.73	0.68	0.33	0.83	0.86		0.29	-0.18	0.77	-0.83	0.39	-0.55	0.79	0.91	0.74	0.76	0.36	-0.35	0.3	0.79	0.86
Common Stock Shares Outstanding	0.4	0.21	0.17	0.33	0.53	0.12	0.27	0.97	0.31	0.39	0.29		0.69	0.39	-0.08	0.4	-0.5	0.03	0.24	0.44	0.42	0.94	0.13	0.37	0.41	0.31
Other Stockholder Equity	-0.16	-0.47	-0.36	-0.23	0.23	-0.49	-0.32	0.54	-0.24	-0.15	-0.18	0.69		-0.01	0.3	0.42	-0.19	-0.57	-0.32	-0.17	-0.08	0.49	0.06	0.46	-0.12	-0.26
Short Term Investments	0.93	0.58	0.6	0.79	0.87	0.7	0.64	0.47	0.9	0.95	0.77	0.39	-0.01		-0.7	0.69	-0.89	0.79	0.68	0.9	0.97	0.47	0.01	0.65	0.96	0.71
Short Long Term Debt Total	-0.73	-0.59	-0.49	-0.64	-0.56	-0.53	-0.41	-0.1	-0.68	-0.76	-0.83	-0.08	0.3	-0.7		-0.41	0.59	-0.75	-0.66	-0.63	-0.69	-0.12	0.39	-0.36	-0.71	-0.81
Property Plant And Equipment Net	0.51	0.08	0.11	0.3	0.74	0.09	0.13	0.36	0.44	0.56	0.39	0.4	0.42	0.69	-0.41		-0.73	0.26	0.2	0.47	0.61	0.33	-0.03	0.98	0.58	0.29
Net Debt	-0.76	-0.33	-0.22	-0.51	-1.0	-0.4	-0.34	-0.53	-0.67	-0.8	-0.55	-0.5	-0.19	-0.89	0.59	-0.73		-0.58	-0.35	-0.79	-0.88	-0.49	-0.22	-0.72	-0.84	-0.47
Retained Earnings	0.9	0.83	0.75	0.87	0.54	0.88	0.8	0.18	0.92	0.9	0.79	0.03	-0.57	0.79	-0.75	0.26	-0.58		0.83	0.87	0.85	0.22	0.01	0.2	0.88	0.83
Non Current Assets Total	0.86	0.88	0.91	0.97	0.31	0.86	0.88	0.33	0.88	0.82	0.91	0.24	-0.32	0.68	-0.66	0.2	-0.35	0.83		0.75	0.72	0.39	-0.26	0.12	0.77	0.9
Non Currrent Assets Other	0.96	0.76	0.69	0.83	0.77	0.81	0.83	0.56	0.94	0.94	0.74	0.44	-0.17	0.9	-0.63	0.47	-0.79	0.87	0.75		0.96	0.57	0.15	0.41	0.96	0.78
Cash And Short Term Investments	0.97	0.64	0.6	0.83	0.86	0.72	0.72	0.51	0.94	0.98	0.76	0.42	-0.08	0.97	-0.69	0.61	-0.88	0.85	0.72	0.96		0.52	0.14	0.58	1.0	0.77
Common Stock Total Equity	0.52	0.38	0.36	0.47	0.52	0.33	0.48	0.99	0.47	0.5	0.36	0.94	0.49	0.47	-0.12	0.33	-0.49	0.22	0.39	0.57	0.52		0.15	0.31	0.53	0.42
Non Current Liabilities Total	0.03	-0.25	-0.37	-0.08	0.23	-0.15	0.0	0.16	0.01	0.02	-0.35	0.13	0.06	0.01	0.39	-0.03	-0.22	0.01	-0.26	0.15	0.14	0.15		0.06	0.1	-0.28
Property Plant And Equipment Gross	0.46	-0.05	0.0	0.24	0.73	0.0	0.05	0.33	0.39	0.51	0.3	0.37	0.46	0.65	-0.36	0.98	-0.72	0.2	0.12	0.41	0.58	0.31	0.06		0.53	0.21
Total Current Assets	0.99	0.69	0.66	0.87	0.82	0.76	0.76	0.51	0.96	0.99	0.79	0.41	-0.12	0.96	-0.71	0.58	-0.84	0.88	0.77	0.96	1.0	0.53	0.1	0.53		0.81
Current Deferred Revenue	0.86	0.8	0.81	0.89	0.44	0.78	0.77	0.38	0.86	0.85	0.86	0.31	-0.26	0.71	-0.81	0.29	-0.47	0.83	0.9	0.78	0.77	0.42	-0.28	0.21	0.81

Click cells to compare fundamentals

Corcept Therapeutics Account Relationship Matchups

Corcept Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	412.3M	571.7M	423.8M	583.4M	621.5M	652.6M
Other Current Liab	30.1M	(11.5M)	39.1M	58.1M	65.4M	68.7M
Total Current Liabilities	41.1M	10.6M	6.9M	81.6M	104.5M	109.7M
Accounts Payable	7.5M	10.6M	6.9M	12.0M	17.4M	18.3M
Cash	315.3M	476.9M	335.8M	436.6M	135.6M	116.6M
Other Current Assets	6.0M	6.7M	10.3M	45.0M	41.6M	43.6M
Total Liab	41.1M	48.4M	48.0M	81.6M	114.8M	120.6M
Common Stock	120K	122K	127K	131K	133K	85.9K
Property Plant Equipment	1.1M	1.7M	1.0M	1.8M	2.0M	2.1M
Total Stockholder Equity	371.2M	523.3M	375.8M	501.8M	506.7M	532.0M
Other Assets	61.1M	52.9M	43.5M	77.5M	89.1M	93.5M
Common Stock Shares Outstanding	122.6M	124.2M	126.0M	116.0M	111.7M	83.1M
Liabilities And Stockholders Equity	412.3M	571.7M	423.8M	583.4M	621.5M	652.6M
Other Stockholder Equity	394.4M	440.3M	180.9M	206.2M	103.4M	98.3M
Short Term Investments	244.7M	364.5M	145.9M	365.3M	232.7M	244.3M
Property Plant And Equipment Net	3.4M	2.5M	514K	1.1M	315K	559.2K
Net Debt	(311.9M)	(474.3M)	(335.3M)	(435.5M)	(135.4M)	(142.2M)
Retained Earnings	(23.6M)	82.5M	195.0M	296.4M	402.5M	422.7M
Non Current Assets Total	59.7M	47.5M	42.4M	84.7M	162.9M	171.0M
Non Currrent Assets Other	10.5M	13.4M	14.4M	17.2M	14.8M	15.5M
Cash And Short Term Investments	315.3M	476.9M	335.8M	436.6M	368.2M	386.6M
Common Stock Total Equity	117K	120K	122K	127K	146.1K	87.7K
Non Current Liabilities Total	1.9M	37.8M	41.0M	9.1M	10.3M	12.7M
Property Plant And Equipment Gross	4.5M	4.2M	514K	1.1M	315K	299.3K
Total Current Assets	352.6M	524.2M	381.4M	498.7M	458.6M	481.6M
Accumulated Other Comprehensive Income	261K	415K	(227K)	(869K)	609K	639.5K
Net Tangible Assets	371.2M	523.3M	375.8M	501.8M	577.1M	606.0M
Retained Earnings Total Equity	(117.7M)	(23.6M)	82.5M	195.0M	224.2M	235.4M
Capital Surpluse	417.2M	457.1M	516.1M	591.3M	680.1M	426.4M
Inventory	17.4M	21.2M	18.0M	17.0M	7.7M	9.6M
Net Receivables	19.9M	26.2M	27.6M	31.1M	41.1M	43.2M
Net Invested Capital	371.2M	523.3M	375.8M	501.8M	506.7M	431.5M
Long Term Investments	39.4M	36.2M	112.3M	4.9M	57.2M	41.7M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Corcept Stock Analysis

When running Corcept Therapeutics' price analysis, check to measure Corcept Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corcept Therapeutics is operating at the current time. Most of Corcept Therapeutics' value examination focuses on studying past and present price action to predict the probability of Corcept Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corcept Therapeutics' price. Additionally, you may evaluate how the addition of Corcept Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC